Back to News
Market Impact: 0.25
Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic
Source: Business Wire
Healthcare & BiotechPrivate Markets & Venture
Altay Therapeutics closed a $37 million Series A financing to advance its first oral DUX4 inhibitor for FSHD into clinical development. The headline provides no further details on the financing terms or clinical timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- Banks, CoreWeave, Nvidia, migration: Australia Briefing
- Bending Spoons Stock Soars on Berkshire’s Increased Stake
- Anduril employee tender offer would value the defense tech startup at $90 billion
- Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
- AI Boom Drives ASML Higher as Nvidia Bets on Europe